DK0726952T3 - Receptor benævnt ACT-4 på overfladen af aktiverede T-celler - Google Patents
Receptor benævnt ACT-4 på overfladen af aktiverede T-cellerInfo
- Publication number
- DK0726952T3 DK0726952T3 DK94931650T DK94931650T DK0726952T3 DK 0726952 T3 DK0726952 T3 DK 0726952T3 DK 94931650 T DK94931650 T DK 94931650T DK 94931650 T DK94931650 T DK 94931650T DK 0726952 T3 DK0726952 T3 DK 0726952T3
- Authority
- DK
- Denmark
- Prior art keywords
- act
- cells
- activated
- sup
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/147,784 US5821332A (en) | 1993-11-03 | 1993-11-03 | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
PCT/GB1994/002415 WO1995012673A1 (fr) | 1993-11-03 | 1994-11-03 | Recepteur situe sur la surface de lymphocytes t actives, appele act-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0726952T3 true DK0726952T3 (da) | 2007-05-14 |
Family
ID=22522890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94931650T DK0726952T3 (da) | 1993-11-03 | 1994-11-03 | Receptor benævnt ACT-4 på overfladen af aktiverede T-celler |
Country Status (12)
Country | Link |
---|---|
US (6) | US5821332A (fr) |
EP (1) | EP0726952B1 (fr) |
JP (3) | JPH09504693A (fr) |
AT (1) | ATE350475T1 (fr) |
AU (5) | AU8065294A (fr) |
CA (1) | CA2175577C (fr) |
DE (1) | DE69434908T2 (fr) |
DK (1) | DK0726952T3 (fr) |
ES (1) | ES2281072T3 (fr) |
HK (1) | HK1001464A1 (fr) |
PT (1) | PT726952E (fr) |
WO (1) | WO1995012673A1 (fr) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
AU782568B2 (en) * | 1994-02-04 | 2005-08-11 | Arthur Allen Vandenbark | T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions II |
US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
AU781082B2 (en) * | 1994-02-04 | 2005-05-05 | Arthur Allen Vandenbark | T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions I |
AU784729B2 (en) * | 1994-02-10 | 2006-06-01 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US20020025551A1 (en) * | 1998-04-09 | 2002-02-28 | Millennium Pharmaceuticals, Inc., A Delaware Corporation | Novel molecules of the t129-related protein family and uses thereof |
US6340569B1 (en) | 1997-11-12 | 2002-01-22 | University Of Pittsburgh | Monoclonal antibody and antigens specific therefor and methods of using same |
US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
CA2321161C (fr) * | 1998-02-24 | 2011-12-20 | Andrew D. Weinberg | Compositions renfermant un agent de liaison du recepteur ox-40 ou un acide nucleique codant pour ledit recepteur 0x-40 et techniques favorisant une reponse immunitaire specifique a un antigene |
GB9916703D0 (en) | 1999-07-16 | 1999-09-15 | Alcami Antonio | Viral protein binding compositions and methods |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2003520828A (ja) * | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート,エルエルシー | Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用 |
WO2003009861A1 (fr) * | 2001-07-24 | 2003-02-06 | Genset S.A. | Agonistes et antagonistes de metabolix utilises dans le traitement des troubles metaboliques |
GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
EP2075256A2 (fr) | 2002-01-14 | 2009-07-01 | William Herman | Ligands ciblés |
JP2005529873A (ja) * | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
DE60317677T2 (de) * | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
JP2006508056A (ja) | 2002-08-28 | 2006-03-09 | イミュネックス・コーポレーション | 心臓血管疾患を治療するための組成物および方法 |
EP1581169A4 (fr) * | 2002-11-08 | 2008-09-17 | Genentech Inc | Compositions et procedes de traitement des maladies liees aux cellules k naturelles |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP2650020B1 (fr) | 2005-05-06 | 2016-08-24 | Providence Health & Services - Oregon | Proteine de fusion trimere immunoglobulinique OX-40 et procedes d'utilisation |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
JP2009518446A (ja) | 2005-12-07 | 2009-05-07 | メダレックス インコーポレーティッド | Ctla−4抗体投与量漸増レジメン |
AR057253A1 (es) | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
BRPI0719409A2 (pt) | 2006-12-18 | 2014-02-11 | Genentch Inc | "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo" |
RU2009135824A (ru) * | 2007-02-27 | 2011-04-10 | Дженентек, Инк. (Us) | Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний |
JP5782385B2 (ja) * | 2009-02-17 | 2015-09-24 | ユーシービー ファーマ ソシエテ アノニム | ヒトox40に対する特異性を有する抗体分子 |
WO2011073180A1 (fr) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique |
CN103153332A (zh) | 2010-09-28 | 2013-06-12 | 卡尔医疗有限公司 | 用于治疗血液恶性肿瘤的组合物和方法 |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
RS58528B1 (sr) | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina |
MY186126A (en) | 2013-03-06 | 2021-06-24 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
BR112015023862A2 (pt) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado |
WO2015135558A1 (fr) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combinaison de vaccination et d'agonistes de ox40 |
WO2015153514A1 (fr) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40 |
KR20170002410A (ko) | 2014-04-03 | 2017-01-06 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | 종양 유도 면역 반응의 효능을 향상시키는 방법 |
CN107106590B (zh) | 2014-10-24 | 2022-10-18 | 阿斯利康(瑞典)有限公司 | 组合 |
DE112016001013T5 (de) | 2015-03-03 | 2017-12-21 | Kymab Limited | Antikörper, verwendungen und verfahren |
MX2017013321A (es) | 2015-04-22 | 2018-07-06 | Curevac Ag | Composicion que contiene arn para tratamiento de enfermedades tumorales. |
MA42043A (fr) | 2015-05-07 | 2018-03-14 | Agenus Inc | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
WO2017009842A2 (fr) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions et méthodes pour le traitement du cancer |
WO2017046746A1 (fr) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Associations thérapeuthiques d'un inhibiteur de la btk et d'une molécule de liaison à gitr, d'un agoniste de 4-1bb, ou d'un agoniste d'ox40 |
EP3356403A2 (fr) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
WO2018033254A2 (fr) | 2016-08-19 | 2018-02-22 | Curevac Ag | Arn pour la cancérothérapie |
EP3532094A1 (fr) | 2016-10-26 | 2019-09-04 | CureVac AG | Vaccins à arnm à nanoparticules lipidiques |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
CA3041340A1 (fr) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation |
US20200121719A1 (en) | 2017-01-06 | 2020-04-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
EP3635097A1 (fr) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Procédés d'utilisation de lymphocytes infiltrant les tumeurs dans un mélanome doublement réfractaire |
KR20200074214A (ko) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
CR20200251A (es) | 2017-11-17 | 2020-07-17 | Iovance Biotherapeutics Inc | Expansión de til de aspirados con aguja fina y biopsias por punción |
WO2019136459A1 (fr) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral |
SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019160829A1 (fr) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
KR20210005138A (ko) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도 |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
JP2022501038A (ja) | 2018-09-20 | 2022-01-06 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 凍結保存腫瘍サンプルからのtilの拡大培養 |
JP2022506586A (ja) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用 |
AU2019377422A1 (en) | 2018-11-05 | 2021-05-27 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
EP3877511A1 (fr) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion de til utilisant des inhibiteurs de la voie akt |
SG11202104630PA (en) | 2018-11-05 | 2021-06-29 | Iovance Biotherapeutics Inc | Selection of improved tumor reactive t-cells |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
JP2022514023A (ja) | 2018-12-19 | 2022-02-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用 |
MX2021011608A (es) | 2019-03-29 | 2021-12-10 | Myst Therapeutics Llc | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
JP2022550783A (ja) | 2019-09-30 | 2022-12-05 | アストラゼネカ・アクチエボラーグ | 併用処置 |
JP2022553389A (ja) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
CN115023270A (zh) | 2019-11-27 | 2022-09-06 | 迈斯特治疗公司 | 使用调节剂产生肿瘤反应性t细胞组合物的方法 |
US20230220341A1 (en) | 2019-12-11 | 2023-07-13 | lovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
CN115427438A (zh) | 2020-02-27 | 2022-12-02 | 迈斯特治疗公司 | 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物 |
EP4146794A1 (fr) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie |
JP2023524108A (ja) | 2020-05-04 | 2023-06-08 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 改良された腫瘍反応性t細胞の選択 |
US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (fr) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
TW202241468A (zh) | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者 |
EP4262827A1 (fr) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Traitement de cancers à l'aide de lymphocytes infiltrant les tumeurs |
JP2023554395A (ja) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療 |
EP4267105A1 (fr) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
EP4267172A1 (fr) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Administration sous-cutanée d'anticorps pd1/pd-l1 |
EP4314068A1 (fr) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
BR112023021665A2 (pt) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | Método para tratar um câncer, e, composição |
TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者 |
CA3235824A1 (fr) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systemes et methodes pour coordonner la fabrication de cellules pour l'immunotherapie specifique d'un patient |
AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (fr) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Lymphocytes infiltrant les tumeurs modifiés pour exprimer des charges utiles |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
WO2024030758A1 (fr) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Récepteurs de costimulation chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires |
WO2024054992A1 (fr) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Procédés de séparation d'agent chélateur |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0432249B1 (fr) * | 1989-06-02 | 1996-09-25 | The Johns Hopkins University School Of Medicine | Anticorps monoclonaux contre la chaine beta de recepteurs d'adhesion de leucocytes, procede de production de ces anticorps et utilisation |
WO1992011870A1 (fr) * | 1991-01-11 | 1992-07-23 | Repligen Corporation | Procede de prevention des lesions inflammatoires |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
DK129594A (da) | 1994-11-11 | 1996-05-12 | Smidth & Co As F L | Fremgangsmåde til fremstilling af klinker i stationær brændingsreaktor |
US6607879B1 (en) * | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
-
1993
- 1993-11-03 US US08/147,784 patent/US5821332A/en not_active Expired - Lifetime
-
1994
- 1994-11-03 ES ES94931650T patent/ES2281072T3/es not_active Expired - Lifetime
- 1994-11-03 AU AU80652/94A patent/AU8065294A/en not_active Abandoned
- 1994-11-03 DK DK94931650T patent/DK0726952T3/da active
- 1994-11-03 WO PCT/GB1994/002415 patent/WO1995012673A1/fr active IP Right Grant
- 1994-11-03 PT PT94931650T patent/PT726952E/pt unknown
- 1994-11-03 CA CA002175577A patent/CA2175577C/fr not_active Expired - Fee Related
- 1994-11-03 JP JP7513094A patent/JPH09504693A/ja not_active Withdrawn
- 1994-11-03 AT AT94931650T patent/ATE350475T1/de active
- 1994-11-03 EP EP94931650A patent/EP0726952B1/fr not_active Expired - Lifetime
- 1994-11-03 DE DE69434908T patent/DE69434908T2/de not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/472,940 patent/US6277962B1/en not_active Expired - Lifetime
-
1998
- 1998-01-16 HK HK98100358A patent/HK1001464A1/xx not_active IP Right Cessation
- 1998-11-26 AU AU94138/98A patent/AU9413898A/en not_active Abandoned
-
2001
- 2001-02-26 AU AU23233/01A patent/AU781998B2/en not_active Ceased
- 2001-05-11 US US09/852,845 patent/US20010044522A1/en not_active Abandoned
-
2004
- 2004-01-23 US US10/762,489 patent/US20040136995A1/en not_active Abandoned
- 2004-03-22 US US10/805,377 patent/US7364733B2/en not_active Expired - Fee Related
-
2005
- 2005-05-27 AU AU2005202316A patent/AU2005202316B2/en not_active Ceased
-
2006
- 2006-09-29 US US11/529,598 patent/US20070077247A1/en not_active Abandoned
- 2006-10-19 JP JP2006285354A patent/JP2007089585A/ja not_active Withdrawn
-
2009
- 2009-03-31 JP JP2009086700A patent/JP2009240311A/ja active Pending
- 2009-12-10 AU AU2009248426A patent/AU2009248426A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040265866A1 (en) | 2004-12-30 |
AU2009248426A1 (en) | 2010-01-07 |
AU2005202316A1 (en) | 2005-06-23 |
JP2007089585A (ja) | 2007-04-12 |
JP2009240311A (ja) | 2009-10-22 |
AU8065294A (en) | 1995-05-23 |
US7364733B2 (en) | 2008-04-29 |
PT726952E (pt) | 2007-04-30 |
AU2005202316B2 (en) | 2010-01-07 |
US20010044522A1 (en) | 2001-11-22 |
EP0726952B1 (fr) | 2007-01-03 |
US5821332A (en) | 1998-10-13 |
AU781998B2 (en) | 2005-06-23 |
HK1001464A1 (en) | 1998-06-19 |
WO1995012673A1 (fr) | 1995-05-11 |
US6277962B1 (en) | 2001-08-21 |
AU9413898A (en) | 1999-02-18 |
JPH09504693A (ja) | 1997-05-13 |
CA2175577A1 (fr) | 1995-05-11 |
DE69434908D1 (de) | 2007-02-15 |
DE69434908T2 (de) | 2007-11-15 |
ATE350475T1 (de) | 2007-01-15 |
AU2323301A (en) | 2001-10-04 |
US20040136995A1 (en) | 2004-07-15 |
ES2281072T3 (es) | 2007-09-16 |
US20070077247A1 (en) | 2007-04-05 |
CA2175577C (fr) | 2008-09-02 |
EP0726952A1 (fr) | 1996-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0726952T3 (da) | Receptor benævnt ACT-4 på overfladen af aktiverede T-celler | |
PT694042E (pt) | Inibidor do factor de crescimento de celulas endoteliais vasculares | |
DK1133559T3 (da) | Human-G-protein-koblet orphan receptor RUP3 | |
NO20041325L (no) | Substanser | |
IS5697A (is) | Uppleysanlegur T-eitilfrumu viðtaki | |
DE69435261D1 (de) | Menschlicher rezeptor h4-1bb | |
MX9400071A (es) | Antagonistas del receptor de endotelina. | |
WO2001018035A3 (fr) | Peptides derives de muc-1 | |
ATE477275T1 (de) | Antikörper gegen cd28 | |
TR199800085A2 (xx) | 8-S�bstit�ye edilmi�-1,3,8-triaza- spiro(4,5)dekan-4-on t�revleri. | |
DK1011704T3 (da) | Tumornekrose-faktor-receptor-afledte peptid-analiger | |
ES2187946T3 (es) | Uso de interleucina-15. | |
BR9510265A (pt) | Analogos aza e aza (n-oxi) de antagonistas receptor glicina/nmda | |
DK0699069T3 (da) | Endothelinreceptorantagonister | |
ATE382058T1 (de) | G-protein-gekoppelte rezeptor-antagonisten | |
PE20010516A1 (es) | Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina | |
ES2129120T3 (es) | Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g. | |
NO20002777D0 (no) | FremgangsmÕte for bekjempelse av fedme | |
DK271889A (da) | Laegemiddel paa basis af en aryloxypropanolamin til selektiv antagonisering af 5-ht1-receptorer | |
DE69809242D1 (de) | Neue pyrimidinderivate | |
ATE196652T1 (de) | In kunstlisches rekombinantes substrat ragg-1 und nativem aggrecan zum studium der proteolytischen wirkung von 'aggrecanase' in zellkultursystemen | |
WO2000052039A3 (fr) | Materiaux de lectomedine et procedes | |
ES2142317T3 (es) | Polipeptidos de proteinas s y uso de los mismos. | |
ES2172939T3 (es) | Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. | |
DK0583352T3 (da) | hGPIIB fragmenter og deres anvendelse i in vitro metoder til bestemmelse af in vivo thrombotiske tilstande |